Market Overview:
The global colorectal cancer diagnostics and therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of colorectal cancer, rising awareness about early diagnosis and treatment options, and technological advancements in colorectal cancer diagnostics and therapeutics. The global colorectal cancer diagnostics market is segmented by type into colonoscopy, fecal occult blood test (FOBT), computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, endoscopic ultrasound (EUS), sigmoidoscopy, and others. The colonoscopy segment is expected to dominate the global colorectal cancer diagnostics market during the forecast period owing to its high accuracy rate for detecting polyps and cancers. The global colorectal cancer therapeutics market is segmented by drug class into chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, hormone therapy drugs,,and others.
Product Definition:
The definition of Colorectal Cancer Diagnostics & Therapeutics is the study and treatment of colorectal cancer. The importance of Colorectal Cancer Diagnostics & Therapeutics is that it can help to improve the diagnosis and treatment of colorectal cancer.
Colorectal Cancer Diagnostics:
Colorectal cancer (CRC) is one of the most common types of cancer occurring in the gastrointestinal tract. According to estimates by the World Cancer Research Fund International, approximately 1.1 million cases were reported and an estimated 92,000 deaths were recorded every year in 2008. The incidence rate is expected to rise over the forecast period due to growing geriatric population base coupled with increasing risk factors such as changes in lifestyle habits and high consumption of animal protein & fat intake.
Colorectal Cancer Therapeutics:
Colorectal cancer is the most common type of cancer in the U.S. According to American Cancer Society, it accounted for 54% of all cancers in 2018 and is expected to be one of the leading causes of deaths by 2030. The disease has a poor prognosis with a survival rate below 5 years due to advanced stage at diagnosis and lack of effective treatment methods available commercially.
Application Insights:
The others application segment held the largest share of over 50.0% in 2017. This is attributed to the increasing prevalence of cancer and rising demand for non-invasive, real-time diagnostic solutions that help in monitoring patient¢â‚¬â„¢s condition & treatment response. The specialty clinics are adopting a personalized approach by integrating genomic data with traditional colorectal cancer biomarkers to improve diagnosis and therapeutics management.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Abbott, Inc.; Aviva Biosciences; BioDirection; Cologuard Inc.; and Procter & Gamble. These companies are engaged in extensive R&D activities for colon cancer detection methods and therapies. For instance, in November 2016, Procter & Gamble collaborated with The Ohio State University Comprehensive Cancer Centre (OSUCCC) to study colorectal cancer biomarkers using OSUCCC’s human biopsy-based assay platform.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of colorectal cancer coupled with increasing awareness about early diagnosis methods across emerging countries such as China and India.
Growth Factors:
- Increasing incidence of colorectal cancer
- Growing demand for early diagnosis and treatment of colorectal cancer
- Rising awareness about colorectal cancer among people
- Technological advancements in the field of diagnostics and therapeutics for colorectal cancer
- Availability of government funding for research on colorectal cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Colorectal Cancer Diagnostics & Therapeutics Market Research Report
By Type
Colorectal Cancer Diagnostics, Colorectal Cancer Therapeutics
By Application
Hospitals, Specialty Clinics, Others
By Companies
Biocept, Cancer Genetics, Foundation Medicine, Sysmex Corporation, Danaher Corporation, Epigenomics, Illumina, Rosetta Genomics, Exact Science Corporation, Pathway Genomics Corporation, Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, Eli Lilly, Sanofi, Regeneron, Bayer, Onyx
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
141
Number of Tables & Figures
99
Customization Available
Yes, the report can be customized as per your need.
Global Colorectal Cancer Diagnostics & Therapeutics Market Report Segments:
The global Colorectal Cancer Diagnostics & Therapeutics market is segmented on the basis of:
Types
Colorectal Cancer Diagnostics, Colorectal Cancer Therapeutics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biocept
- Cancer Genetics
- Foundation Medicine
- Sysmex Corporation
- Danaher Corporation
- Epigenomics
- Illumina
- Rosetta Genomics
- Exact Science Corporation
- Pathway Genomics Corporation
- Taiho Pharma
- Merck KGaA
- Amgen
- Takeda
- Roche
- Eli Lilly
- Sanofi
- Regeneron
- Bayer
- Onyx
Highlights of The Colorectal Cancer Diagnostics & Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Colorectal Cancer Diagnostics
- Colorectal Cancer Therapeutics
- By Application:
- Hospitals
- Specialty Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Colorectal Cancer Diagnostics & Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Colorectal cancer diagnostics and therapeutics is the study of how to diagnose, treat, and prevent colorectal cancer.
Some of the major players in the colorectal cancer diagnostics & therapeutics market are Biocept, Cancer Genetics, Foundation Medicine, Sysmex Corporation, Danaher Corporation, Epigenomics, Illumina, Rosetta Genomics, Exact Science Corporation, Pathway Genomics Corporation, Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, Eli Lilly, Sanofi, Regeneron, Bayer, Onyx.
The colorectal cancer diagnostics & therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Colorectal Cancer Diagnostics & Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Colorectal Cancer Diagnostics & Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Colorectal Cancer Diagnostics & Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Colorectal Cancer Diagnostics & Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Colorectal Cancer Diagnostics & Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Colorectal Cancer Diagnostics & Therapeutics Market Size and Y-o-Y Growth
4.5.2 Colorectal Cancer Diagnostics & Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Colorectal Cancer Diagnostics & Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Type
5.2.1 Colorectal Cancer Diagnostics
5.2.2 Colorectal Cancer Therapeutics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Colorectal Cancer Diagnostics & Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Colorectal Cancer Diagnostics & Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Colorectal Cancer Diagnostics & Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Type
9.6.1 Colorectal Cancer Diagnostics
9.6.2 Colorectal Cancer Therapeutics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Colorectal Cancer Diagnostics & Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Type
10.6.1 Colorectal Cancer Diagnostics
10.6.2 Colorectal Cancer Therapeutics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Colorectal Cancer Diagnostics & Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Type
11.6.1 Colorectal Cancer Diagnostics
11.6.2 Colorectal Cancer Therapeutics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Colorectal Cancer Diagnostics & Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Type
12.6.1 Colorectal Cancer Diagnostics
12.6.2 Colorectal Cancer Therapeutics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Colorectal Cancer Diagnostics & Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Type
13.6.1 Colorectal Cancer Diagnostics
13.6.2 Colorectal Cancer Therapeutics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Colorectal Cancer Diagnostics & Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Colorectal Cancer Diagnostics & Therapeutics Market: Competitive Dashboard
14.2 Global Colorectal Cancer Diagnostics & Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biocept
14.3.2 Cancer Genetics
14.3.3 Foundation Medicine
14.3.4 Sysmex Corporation
14.3.5 Danaher Corporation
14.3.6 Epigenomics
14.3.7 Illumina
14.3.8 Rosetta Genomics
14.3.9 Exact Science Corporation
14.3.10 Pathway Genomics Corporation
14.3.11 Taiho Pharma
14.3.12 Merck KGaA
14.3.13 Amgen
14.3.14 Takeda
14.3.15 Roche
14.3.16 Eli Lilly
14.3.17 Sanofi
14.3.18 Regeneron
14.3.19 Bayer
14.3.20 Onyx
